Fibrosis News and Research

RSS

Fibrosis is the growth of fibrous tissue.

New technique promotes dramatic increase in cardiac function

LoneStar Heart Inc., today announced the advancement of a new therapeutic strategy aimed at genetic reprogramming of cardiac fibroblasts into functioning heart muscle cells to treat damage following a heart attack and other forms of heart disease.

30 May 2012

Corrected interim data from Vertex VX-809, KALYDECO combination Phase 2 study for CF

Vertex Pharmaceuticals Incorporated announced today a correction to the previously reported responder analysis, as well as additional data from, the recent interim analysis of an ongoing Phase 2 study of VX-809 and KALYDECO that showed significant improvements in lung function among adults with cystic fibrosis who have two copies of the most common mutation in the cystic fibrosis transmembrane conductance regulator gene, F508del.

30 May 2012

NAC may be an effective therapy for some features of autism

A specific antioxidant supplement may be an effective therapy for some features of autism, according to a pilot trial from the Stanford University School of Medicine and Lucile Packard Children's Hospital that involved 31 children with the disorder.

30 May 2012

Including smokers in donor pool improves survival rates for patients on lung transplant waiting lists and should be continued

New research shows that lung transplant patients who receive the lungs of smokers have a better overall chance of survival than those who remain on waiting lists, despite the fact that they tend to survive for a shorter period after transplantation than those who receive the lungs of non-smokers.

29 May 2012

European CHMP issues positive opinion to Vertex's KALYDECO for treatment of CF

Vertex Pharmaceuticals Incorporated announced today that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion by consensus recommending the approval of KALYDECO (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

25 May 2012

University of Kentucky researcher receives $1.8M NIH grant to study CF

David Feola, a University of Kentucky College of Pharmacy faculty member in the Department of Pharmacy Practice and Science, received a five-year, $1.8 million grant from the National Institutes of Health (NIH) to continue his research investigating immune responses in the lungs that will potentially lead to the discovery of medical treatments for patients with cystic fibrosis and other chronic pulmonary inflammatory conditions.

25 May 2012

Oestrogen promotes presence of 'mucoid' form of P. aeruginosa in women with CF

Researchers from the Respiratory Research Division of the Department of Medicine, Royal College of Surgeons in Ireland (RCSI) have published a study which represents a major breakthrough in understanding why females with cystic fibrosis do worse than males.

25 May 2012

COPD patients with P. aeruginosa infection more likely to have poor clinical outcomes

Patients with chronic obstructive pulmonary disease (COPD) who become infected with the bacterium Pseudomonas aerguinosa are more likely to have worse clinical outcomes and experience more hospitalizations during the course of their disease than COPD patients who are not infected, according to researchers from Buffalo, N.Y.

24 May 2012

Many women not screened for gonorrhea and chlamydia infection during pregnancy

Many women are not screened for chlamydia and gonorrhea infection during their pregnancy, and follow-up testing is not always performed as medically recommended for those who test positive for chlamydia, according to a study published online in the American Journal of Obstetrics and Gynecology.

From Quest Diagnostics 24 May 2012

Results from Boehringer Ingelheim’s Respimat Phase II study on moderate, persistent asthma

Boehringer Ingelheim announced today results from a Phase II study evaluating the investigational compound tiotropium delivered once-daily via the Respimat Inhaler in adolescents with symptomatic, moderate persistent asthma.

23 May 2012

Failing combination asthma therapy may lead to SAFS in children

New research presented at the ATS 2012 International Conference in San Francisco suggests that a significant proportion of children with asthma failing Step 4 or greater therapy may have severe asthma with fungal sensitization (SAFS).

23 May 2012

Sarcoidosis accounts for 25% of all deaths in African-American women

A new study conducted by researchers from Boston University has found that sarcoidosis accounts for 25 percent of all deaths among women in the Black Women's Health Study who have the disease. The study is the largest epidemiologic study to date to specifically address mortality in black females with sarcoidosis.

23 May 2012

NIEHS renews funding for SRP at UCSD

The National Institute of Environmental Health Sciences (NIEHS), part of the National Institutes of Health, has renewed funding for the Superfund Research Program (SRP) at the University of California, San Diego. Over the next five years, the $15 million grant will fund continued research on the molecular and genetic consequences of exposure to uncontrolled toxicants from Superfund and other hazardous waste sites.

23 May 2012

UAB creates Program in Environmental and Translational Medicine

The University of Alabama at Birmingham has created a Program in Environmental and Translational Medicine, a multi-faceted approach to dealing with health issues tied to environmental origins.

22 May 2012

InterMune reaches definitive agreement with Vidara to sell Actimmune

InterMune, Inc. today announced that it has reached a definitive agreement with Vidara Therapeutics International Limited (Vidara) to sell its rights to Actimmune (interferon gamma-1b) in a cash transaction valued at $55 million plus a two-year royalty stream.

22 May 2012

$Children with pelvic and thigh fractures rarely develop dangerous blood clots$

Children with pelvic and thigh fractures rarely develop dangerous blood clots

Children with pelvic and thigh fractures develop dangerous blood clots so rarely that anti-clotting therapy should be given only to those with underlying conditions that increase clotting risk, according to a study from Johns Hopkins Children's Center.

21 May 2012

Young children with cystic fibrosis do not benefit from concentrated saline therapy

Concentrated saline therapy not effective in young children with cystic fibrosis NIH-funded study demonstrates importance of conducting pediatric clinical trials.

21 May 2012

Hypertonic saline does not reduce rate of pulmonary exacerbations in young children with CF

Margaret Rosenfeld, M.D., M.P.H., of Seattle Children's Hospital, and colleagues conducted a study to examine if hypertonic saline would reduce the rate of pulmonary exacerbations in children younger than 6 years of age with cystic fibrosis.

21 May 2012

Osteopenia/osteoporosis more prevalent among male patients with pulmonary disease

There is a very high prevalence of osteopenia/osteoporosis among male patients with pulmonary disease, according to a new study from researchers in California.

21 May 2012

Three-drug combo harmful for patients with idiopathic pulmonary fibrosis

A combination of three drugs used worldwide as the standard of care for a serious lung disease puts patients in danger of death or hospitalization, and should not be used together to treat the disease, called idiopathic pulmonary fibrosis, according to the surprising results of a rigorous independent study.

21 May 2012